ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC by Dr. Edward Garon

Article

GALAXY-1 TrialDr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.

 

[powerpress]

Heat Shock Protein Inhibition Provides Another Encouraging Signal for Some Lung Adenocarcinoma Patients with a Worse Prognosis

Article

Historically, lung cancer patients with a KRAS mutation, which is the molecular marker that is actually most common in patients with NSCLC (about 20-25%), have not had extremely appealing treatment options.  In fact, the available data has largely led to the conclusion that both chemotherapy and EGFR inhibitor therapy tends to be, if anything, somewhat less effective for people with a KRAS mutation.  Despite some reason for hope in early research with a few novel therapies, there really hasn't been a good alternative that is specifically effective for KRAS mutation-positive patients until t

Dr. Ben Solomon on ALK Inhibition: From Science to Effective Treatment for ALK-Positive NSCLC

Article

Several weeks ago, we were fortunate enough to be joined by not one but two international stars in lung cancer research that is being translated directly from lab bench to bedside of the patient. I don't think there's a more clear and inspiring example of good science leading to effective therapy, albeit for a limited patient population, than the story of the anaplastic lymphoma kinase (ALK) inhibitor crizotinib (recently FDA approved and commercially launched as XALKORI) for patients with an EML4-ALK rearrangement (approximately 4% of the broader NSCLC population). Drs.

HSP 90 Inhibitors: Another Rational Choice for Patients with Acquired Resistance to EGFR Inhibitors

Article

Continuing Dr. West's theme discussing new therapies for patients with acquired resistance, I'd like to answer a few questions about HSP 90 inhibitors that have caught my attention on GRACE over the past few weeks, and in particular, highlight my "pet" targeted agent, AUY922. HSP 90 inhibitors are drugs that many of you already know about-they are being studied in patients with ALK(+)lung cancer and as a 2nd line therapy option for all patients with lung cancer with Taxotere.

Heat Shock Protein Inhibitor IPI-504: Particularly Active for Patients with an ALK Rearrangement?

Article

I've written in the past about a class of proteins known as heat shock protein inhibitors as a targeted anticancer therapy, and there are a few that have been in clinical trials, including IPI-504 from Infinity Pharmaceuticals and STA-9090 from Synta Pharmaceuticals, with others also in development. The only trial that has actually been the subject of a completed clinical trial in NSCLC is IPI-504. Dr.